DPP-4i Treatment Doesn't Up MI, Stroke Risk in Seniors

This article originally appeared here.
Share this content:
DPP-4i Treatment Doesn't Up MI, Stroke Risk in Seniors
DPP-4i Treatment Doesn't Up MI, Stroke Risk in Seniors

FRIDAY, Feb. 24, 2017 (HealthDay News) -- For older U.S. Medicare beneficiaries, dipeptidyl peptidase-4 inhibitors (DPP-4i) treatment is not associated with increased cardiovascular (CV) risk relative to sulfonylureas (SU) and thiazolidinediones (TZD), according to a study published online Feb. 14 in Diabetes, Obesity and Metabolism.

Mugdha Gokhale, Ph.D., from the University of North Carolina at Chapel Hill, and colleagues identified two new-user cohorts of Medicare beneficiaries aged >65 years: DPP-4i versus SU (30,130 and 68,382 initiators, respectively) and DPP-4i versus TZD (20,596 and 13,526, respectively) during 2007 to 2013.

The researchers found that the hazard ratio for the composite outcome (myocardial infarction [MI], stroke, and all-cause mortality) was 0.75 (95 percent confidence interval [CI], 0.72 to 0.79) in the DPP-4i versus SU comparison. For DPP-4i and SU, respectively, the one-year risks for MI were 1.00 (95 percent CI, 0.89 to 1.12) and 1.47 (95 percent CI, 1.38 to 1.56) per 100 patients; the corresponding numbers for stroke risk were 0.98 (95 percent CI, 0.87 to 1.10) and 1.09 (95 percent CI, 1.01 to 1.17). For DPP-4i versus TZD, the hazard ratio for the composite outcome was 0.94 (95 percent CI, 0.86 to 1.02). The one-year risks for MI and stroke were about 0.90 and 0.80, respectively, per 100 patients for both DPP-4i and TZD.

"Though limited by the short treatment duration, our study suggests no increased short-term risk of MI stroke or heart failure with DPP-4i versus SU/TZD," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Higher Risk of Adverse Outcomes for Births to Young CA Survivors

Higher Risk of Adverse Outcomes for Births to ...

Increased risks among live births for adolescent and young adult cancer survivors

Many Youths With Diabetes Not Receiving Eye Examinations

Many Youths With Diabetes Not Receiving Eye Examinations

Racial minorities less likely to undergo eye exam; increasing net worth increases likelihood of eye exam

Mortality Risk Impacts Colon CA Screening in Dialysis Patients

Mortality Risk Impacts Colon CA Screening in Dialysis ...

Higher rate of screening among patients most likely to receive a transplant

is free, fast, and customized just for you!

Already a member?

Sign In Now »